Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK drug, exec says
Summary : After a high-profile study turned up safety risks for Pfizer’s JAK inhibitor Xeljanz last year, the FDA put the entire…
Summary : After a high-profile study turned up safety risks for Pfizer’s JAK inhibitor Xeljanz last year, the FDA put the entire…
SUMMARY: Sym-Agro with Asfertglobal has announced an exclusive distribution agreement, a leader in the production of biostimulants, biocontrol solutions, and crop stress…